The exclusive license includes issued patents and technology, including formulations.
In clinical studies, one topical formulation improved nipple sensitivity and alleviated associated sexual problems.
The product has been named JW-500 to be added to a line of other clinical stage products currently under development.
Jupiter Wellness plans to file for a pre-IND meeting with the FDA within the next 12 months and intends to seek Orphan Drug Designation.
Price Action: JUPW shares are trading higher by 1.63% at $1.05 on the last check Tuesday.
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.